Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Do BRAF inhibitors select for populations with different disease progression kinetics?

Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N.

J Transl Med. 2013 Mar 8;11:61. doi: 10.1186/1479-5876-11-61.

2.

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N.

J Transl Med. 2012 May 28;10:107. doi: 10.1186/1479-5876-10-107.

3.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
4.

Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".

Jarkowski A 3rd, Norris L, Trinh VA.

Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23. Review.

PMID:
25056920
5.

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.

Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ.

Cancer Biol Ther. 2015;16(5):662-70. doi: 10.1080/15384047.2015.1026507.

6.

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.

Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31.

PMID:
24484235
7.

Which drug, and when, for patients with BRAF-mutant melanoma?

Jang S, Atkins MB.

Lancet Oncol. 2013 Feb;14(2):e60-9. doi: 10.1016/S1470-2045(12)70539-9. Review.

PMID:
23369684
8.

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.

Schreuer MS, Chevolet IL, Jansen YJ, Seremet TC, Wilgenhof S, Liénard D, Del Marmol V, Neyns B.

Melanoma Res. 2015 Feb;25(1):68-74. doi: 10.1097/CMR.0000000000000131.

PMID:
25396684
9.

Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.

Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H, Neyns B.

Anticancer Res. 2012 Apr;32(4):1355-9.

PMID:
22493370
10.

Systemic treatment for BRAF-mutant melanoma: where do we go next?

Menzies AM, Long GV.

Lancet Oncol. 2014 Aug;15(9):e371-81. doi: 10.1016/S1470-2045(14)70072-5. Review.

PMID:
25079100
11.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
12.

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.

Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.

Cancer. 2014 Jun 1;120(11):1695-701. doi: 10.1002/cncr.28620. Epub 2014 Feb 27.

13.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
14.

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.

Menzies AM, Long GV.

Eur J Cancer. 2013 Oct;49(15):3229-41. doi: 10.1016/j.ejca.2013.06.027. Epub 2013 Jul 16. Review.

PMID:
23870385
15.

Gaining momentum: New options and opportunities for the treatment of advanced melanoma.

Michielin O, Hoeller C.

Cancer Treat Rev. 2015 Sep;41(8):660-70. doi: 10.1016/j.ctrv.2015.05.012. Epub 2015 Jun 4. Review.

PMID:
26096079
16.

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV.

Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1.

17.

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.

Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR.

Cancer Immunol Immunother. 2012 May;61(5):733-7. doi: 10.1007/s00262-012-1227-3. Epub 2012 Mar 1.

PMID:
22382362
18.

Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities.

Zahnreich S, Mayer A, Loquai C, Grabbe S, Schmidberger H.

Future Oncol. 2016 Jan;12(1):95-106. doi: 10.2217/fon.15.297. Epub 2015 Nov 30. Review.

PMID:
26616061
19.

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.

Martin-Liberal J, Larkin J.

Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252. Review.

PMID:
25686114
20.

[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].

Schadendorf D.

J Dtsch Dermatol Ges. 2011 Apr;9(4):340. doi: 10.1111/j.1610-0387.2011.07653.x. German. No abstract available.

PMID:
21439018

Supplemental Content

Support Center